THE RESEARCH RECORD

The short version

Melanotan II works by activating four melanocortin receptors simultaneously — MC1R, MC3R, MC4R, and MC5R. That's the central pharmacological fact, and it explains everything downstream: you cannot get the tanning effect (MC1R) without also hitting the receptors that drive appetite suppression, thermogenesis, and pro-erectile signaling (MC4R). The controlled human research is thin: three studies, 23 subjects, done at the University of Arizona between 1996 and 2000. Two showed significant results at their stated endpoints. Everything since has been animal pharmacology, case reports, and qualitative research documenting what happens when the compound circulates on the unregulated internet. The derived compound — bremelanotide — went through FDA approval for a sexual-dysfunction indication. Melanotan II itself was never approved for anything.

Receptor Pharmacology: The Nonselective Problem

Every pharmacological fact about Melanotan II downstream follows from one structural decision: it is a nonselective melanocortin receptor agonist. MT-II binds MC1R (skin pigmentation), MC3R (energy homeostasis feedback), MC4R (appetite, thermogenesis, sexual function), and MC5R (exocrine gland regulation). It does not bind MC2R, the adrenocorticotropin-specific receptor. At research doses documented in human trials, the binding profile hits all four of the above targets simultaneously.

MC1R signaling is the melanogenesis pathway. Binding activates adenylyl cyclase, raises intracellular cAMP, activates protein kinase A, upregulates MITF transcription factor activity, and increases tyrosinase expression — the rate-limiting enzyme in melanin biosynthesis. MT-II shifts melanin synthesis preferentially toward eumelanin, the brown-to-black form, in a process that can proceed in the absence of UV exposure, though the magnitude of pigmentation response appears to be amplified by concurrent UV exposure ^[12].

MC4R signaling drives the other cluster of effects that define MT-II's research profile. Hypothalamic paraventricular nucleus MC4R activation produces central sympathomimetic efferents: appetite suppression, increased thermogenesis in brown adipose tissue, and pro-erectile signaling ^{[4][5][6][17]}. The pro-erectile mechanism was the serendipitous finding of the 1996 Arizona tanning pilot, where one of three male subjects reported spontaneous erections lasting one to five hours post-injection of 0.025 mg/kg subcutaneous ^[1].

The nonselective binding profile is not a technical footnote. It is the reason MT-II was never approved — and the reason bremelanotide, the derived compound approved in 2019 for hypoactive sexual desire disorder, is a different molecule. Bremelanotide carries a C-terminal free acid in place of MT-II's amide, which substantially reduces MC1R (pigmentation) activity while preserving MC4R agonism. MT-II with its amide terminus remains nonselective; its tanning and pro-erectile effects cannot be separated at doses studied so far ^[17].

The Arizona Trials: What Was Actually Studied

The University of Arizona team ran the first controlled human MT-II studies in the mid-1990s under formal investigational drug research protocols. Three studies constitute the entirety of the controlled human literature.

The 1996 Dorr et al. phase I tanning pilot enrolled three healthy male volunteers receiving subcutaneous injections at escalating doses of 0.01–0.025 mg/kg over two weeks ^[1]. Two of three subjects showed measurable pigmentation increases in face, upper body, and buttocks by clinical assessment. Adverse events included mild nausea, somnolence, yawning, and in one subject, unprompted penile erection lasting one to five hours. This is the complete controlled human tanning dataset for MT-II: n=3, two responders, no placebo arm, no long-term follow-up.

The Wessells et al. 1998 study ^[2] ran a double-blind, placebo-controlled crossover design in 10 men with psychogenic erectile dysfunction, giving a single subcutaneous injection of MT-II at 0.025 mg/kg or placebo at each crossover visit. RigiScan monitoring showed clinically apparent erections in 8 of 10 subjects on MT-II versus none on placebo. Mean duration of tip rigidity greater than 80% was 38.0 minutes on MT-II versus 3.0 minutes on placebo (p=0.0045). Nausea was the primary adverse event.

The 2000 Wessells et al. study ^[3] extended the crossover design to 10 men with organic erectile dysfunction — vascular, neurogenic, or mixed etiology — a population generally less responsive to any erectogenic intervention. MT-II (0.025 mg/kg SC) produced subjective erections in 12 of 19 injections versus 1 of 21 placebo doses. Again, nausea was the most common adverse event, and the pro-erectile effect was statistically significant even in this harder population.

A 2007 review by King, Mayorov, Balse-Srinivasan, Hruby, Vanderah, and Wessells established MC4R as the primary mediator of melanocortin-induced erection and documented that melanocortin agonists address the libido and desire component of sexual response — a different mechanism from phosphodiesterase-5 inhibitors, which work on the vascular end of the response ^[17]. This mechanistic distinction is what drove the Palatin Technologies development program for bremelanotide.

After 2000, no additional controlled human trials of MT-II were conducted. Clinical development moved to the derived compound.

Rodent Model Findings: Appetite, Fat, and Stress

The animal literature extends MT-II's studied effects beyond the three clinical endpoints covered in human trials. Three rodent findings are particularly documented.

Feeding behavior: Eliason et al. (2022) ^[4] demonstrated that bilateral microinjection of MT-II at 0.3 nmol per side into the nucleus accumbens of male C57BL/6J mice produced dose-dependent suppression of both lever-pressing for food access (appetitive motivation) and home-cage food intake (consumptive responding), with intake suppression persisting for 24 hours at the 0.3 nmol dose. Importantly, the effect did not involve taste aversion or motor impairment — animals moved normally, they simply sought food less and consumed less when it was available. This implicates mesolimbic MC4R specifically in the reward-linked feeding circuit, a more granular mechanistic finding than whole-animal appetite suppression.

Adipose tissue: Strader et al. (2007) ^[8] showed that MT-II treatment in diet-induced obese mice reduced both visceral and subcutaneous adipose tissue beyond what was accounted for by caloric restriction alone. Pair-fed controls losing equivalent weight retained more fat mass than MT-II-treated animals, indicating a direct metabolic mechanism independent of appetite suppression. The study did not identify the specific downstream pathway, but the finding suggests MC4R activation effects on adipose tissue are not entirely mediated through food intake reduction.

NPY antagonism: Raposinho, White, and Aubert (2003) ^[6] infused MT-II at 15 nmol/day ICV alongside NPY at 5 nmol/day for seven days in male Sprague-Dawley rats. MT-II cancelled NPY-driven hyperphagia and substantially reduced NPY-induced fat pad weight doubling and elevated insulin and leptin levels. Notably, MT-II did not reverse NPY-mediated suppression of gonadotropic or somatotropic axes, indicating that the melanocortin and NPY circuits are functionally discrete in those hormonal domains — an architectural finding for how these signaling systems interact.

Thermogenesis: McMillan et al. (2021) ^[5] studied daily peripheral MT-II injection in PACAP-deficient female mice during cold acclimation and found partial restoration of thermogenic capacity and correction of impaired lipid mobilization in response to adrenergic stimulation. The finding positions PACAP as upstream of the melanocortin system in brown adipose thermogenesis and demonstrates that MT-II can rescue some — though not all — of the thermogenic deficit caused by PACAP deficiency.

Nerve regeneration: Ter Laak et al. (2003) ^[7] found that subcutaneous MT-II at 20 μg/kg every 48 hours significantly enhanced sensory recovery following sciatic nerve crush lesion in male Wistar rats. The same dosing provided partial neuroprotection against cisplatin-induced toxic neuropathy. This was the first demonstration of an α-MSH analog's efficacy in peripheral nerve regeneration.

Toxicology: The Case Report Record

The controlled clinical literature enrolled 23 subjects in three studies, all conducted before 2001. The toxicology literature began accumulating in the 2010s, when internet sales of lyophilized MT-II created a population of unsupervised self-administrators operating well outside the dose ranges of the phase I studies.

Rhabdomyolysis and acute kidney injury: Nelson, Bryant, and Aks (2012) ^[9] reported a 39-year-old male who self-injected 6 mg of internet-purchased MT-II subcutaneously — approximately six times higher than doses in the research trials. He developed sympathomimetic excess with CPK elevation to 17,773 IU/L, creatinine rise to 2.25 mg/dL, tachycardia, hypertension, diffuse myalgia, and tremors. ICU admission was required; full recovery followed after three days with benzodiazepines and IV bicarbonate. This case established the sympathomimetic toxidrome as the overdose presentation.

Ischemic priapism: Devlin, Pomerleau, and Foote (2013) ^[10] reported a 60-year-old man who self-injected 10 mg subcutaneously — approximately 40 times higher than phase I research doses — and developed a painful erection within 30 minutes, progressing to ischemic priapism requiring emergency intervention. Mallory, Lopategui, and Cordon (2021) ^[11] reported a more striking case: a 55-year-old man with six years of MT-II use who developed ischemic priapism lasting 30 hours after a 2 mg injection — a dose within the range of typical self-reported use. Intracavernous phenylephrine and saline irrigation were insufficient; penoscrotal decompression surgery was required. At 15-week follow-up, he had new-onset erectile dysfunction with corpora fibrosis and non-response to PDE5 inhibitors. This case documents serious irreversible sequelae even at doses below overdose range after repeated exposure.

Renal infarction: Peters, Hadimeri et al. (2020) ^[18] reported a patient who injected 6 mg MT-II subcutaneously and was subsequently found on CT to have a right renal infarction affecting approximately 50% of the kidney. This was the first MT-II-associated renal infarction reported to the Swedish toxicovigilance system. The mechanism was postulated to involve thrombotic pharmacological effects and possible direct renal parenchymal toxicity.

Melanoma and dermatology risk: Hjuler and Lorentzen (2014) ^[12] reported a 20-year-old fair-skinned woman who self-injected MT-II for three to four weeks in conjunction with sunbed use and developed a melanoma-associated melanocytic lesion on her left gluteal region. The dermatology literature also documents eruptive dysplastic nevi: a 25-year-old man using MT-II developed a sudden eruption of more than 100 melanocytic nevi, many clinically and dermoscopically atypical, with histopathology revealing severe dysplasia in three biopsied specimens ^[13]. The mechanism proposed for both findings is uncontrolled melanocyte proliferation from prolonged nonselective MC1R stimulation.

Oral mucosal pigmentation: Bonchev (2026) ^[14] documented the first systematically monitored case of MT-II-induced oral mucosal pigmentation. A 42-year-old male received 0.4 mg per injection over 32 injections (12.8 mg total, 64 days) and developed brown pigmentation on attached gingiva and buccal mucosa with irregular poorly-defined borders. At three-month post-discontinuation follow-up, gingival pigmentation persisted with reduced intensity. This case established dentists as a potential point of detection for unregulated MT-II use.

The pattern across the toxicology record: most serious adverse events involve dose levels substantially above the phase I research doses (0.01–0.025 mg/kg), with internet-sourced compound being self-administered at doses with no clinical research basis. The priapism case from Mallory et al. ^[11] — where serious harm occurred at a typical community self-report dose after years of repeated use — represents the exception and is particularly notable.

Recent Findings: Stress, Social Media, and User Behavior

The 2024–2026 literature extends MT-II research in two directions: preclinical pharmacology and behavioral epidemiology.

Antidepressant-like effects: Inozemtseva et al. (2024) ^[15] administered MT-II at 60 nmol/kg body weight intraperitoneally daily to male Sprague-Dawley rats exposed to chronic unpredictable stress (CUS). MT-II reversed or substantially attenuated CUS-induced anhedonia, body weight suppression, adrenal hypertrophy, and decreased hippocampal BDNF levels. The finding positions noncorticotropic melanocortin signaling as a candidate mechanism in stress-resilience circuits — a novel research direction for a compound whose human literature has focused exclusively on pigmentation and sexual function.

User behavior research: Two 2024 British Journal of Dermatology publications and one 2025 JAAD study document MT-II's community use profile. Gilhooley, Daly, and McKenna (2021) ^[16] analyzed 623 online discussion entries from 205 UK and Ireland MT-II users and found that side effects were frequently interpreted as proxies for product authenticity rather than deterrents. McKenzie et al. (2024) ^[19] interviewed 28 self-reported MT-II users and found all achieved skin darkening; most concealed MT-II use from healthcare providers due to anticipated stigma or physician knowledge gaps. A 2025 JAAD qualitative study ^[21] of 29 users found widespread misperception of MT-II as protective against skin cancer — the opposite of what the dermatology literature suggests when MC1R stimulation is combined with UV exposure.

The systematic social media review by O'Mahony et al. (2024) ^[20] analyzed TikTok content on Melanotan and found overwhelmingly positive framing with virtually no representation of adverse effects. The study called for platform-level public health intervention and improved dermatology patient counseling frameworks.